León-González, Antonio JJiménez-Vacas, Juan MFuentes-Fayos, Antonio CSarmento-Cabral, AndreHerrera-Martínez, Aura DGahete, Manuel DLuque, Raúl M2025-01-072025-01-072021-07-23https://hdl.handle.net/10668/28264Metabolic syndrome is associated with chronic diseases, including type 2 diabetes, cardiovascular diseases, and cancer. This review summarizes the current evidence on the antitumor effects of some relevant drugs currently used to manage metabolic-related pathologies (i.e. insulin and its analogs, metformin, statins, etc.) in endocrine-related cancers including breast cancer, prostate cancer, pituitary cancer, ovarian cancer, and neuroendocrine neoplasms. Although current evidence does not provide a clear antitumor role of several of these drugs, metformin seems to be a promising chemopreventive and adjuvant agent in cancer management, modulating tumor cell metabolism and microenvironment, through both AMP-activated protein kinase-dependent and -independent mechanisms. Moreover, its combination with statins might represent a promising therapeutic strategy to tackle the progression of endocrine-related tumors. However, further studies are needed to endorse the clinical relevance of these drugs as adjuvants for cancer chemotherapy.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Cancerinsulinmetabolic syndromemetforminstatinsDiabetes Mellitus, Type 2Endocrine Gland NeoplasmsHumansHypoglycemic AgentsInsulinMetforminTumor Microenvironmentresearch article34311387open access10.1016/j.coph.2021.06.0021471-4973https://doi.org/10.1016/j.coph.2021.06.002